Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
The Methodist Hospital System Bristol-Myers Squibb ImClone LLC |
---|---|
Information provided by: | The Methodist Hospital System |
ClinicalTrials.gov Identifier: | NCT00448097 |
The purpose of this study is to differentiate between the administrations of Cetuximab alone vs. Cetuximab plus Docetaxel in the treatment of non-metastatic prostate cancer before the surgical removal of the prostate.
Condition | Intervention | Phase |
---|---|---|
Prostatic Neoplasms |
Drug: cetuximab Drug: docetaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate |
Enrollment: | 7 |
Study Start Date: | February 2007 |
Study Completion Date: | August 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
With the larger number of men who undergo screening with assays for serum prostate specific antigen, urologists continue to see considerable numbers of patients with locally advanced prostate disease. There is a higher risk of treatment failure in any patient with a tumor that extends through the prostate capsule, more aggressive pathology (Gleason score of 7 or higher), or patients with a PSA of greater than 10 ng/ml. The rationale for adding molecular targeted drugs such as Cetuximab (epithelial growth factor inhibitor), with or without chemotherapy such as Docetaxel, is that such therapy has the potential to demonstrate tumor shrinkage of the prostate and, in addition, micrometastatic cells. Cetuximab alone or Cetuximab plus Docetaxel utilizing the preprostatectomy model, with the adjuvant delivery of Cetuximab for 6 months, will provide data for the following points:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
The Methodist Hospital Research Institute | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Robert J Amato, DO | The Methodist Hospital Research Institute |
Responsible Party: | The Methodist Hospital Research Institute ( Robert J. Amato, DO ) |
Study ID Numbers: | E-VS-ET-2006, 0206-0027 |
Study First Received: | March 14, 2007 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00448097 History of Changes |
Health Authority: | United States: Institutional Review Board |
Adenocarcinoma of the Prostate Prostate cancer Pre-Prostatectomy Neoadjuvant |
Docetaxel Prostatic Diseases Genital Neoplasms, Male Cetuximab |
Urogenital Neoplasms Genital Diseases, Male Adenocarcinoma Prostatic Neoplasms |
Docetaxel Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male Antineoplastic Agents |
Therapeutic Uses Cetuximab Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms Pharmacologic Actions |